Fulcrum Therapeutics (FULC) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Larimar Therapeutics (LRMR) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 41.7% versus a loss of 60.3%. Over five years, LRMR leads with a -77.3% price change compared with -85.9% for FULC. Larimar Therapeutics is the larger company by market cap ($285.7 million vs $280.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | LRMR |
|---|---|---|
| Share price | $3.67 | $2.75 |
| Market cap | $280.01M | $285.68M |
| 1-day change | -0.54% | -1.08% |
| YTD return | -67.55% | -27.82% |
| 1-year return | -60.28% | -41.74% |
| 5-year return | -85.88% | -77.31% |
| EPS (TTM) | $-1.21 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $6.42 |
| 52-week low | $2.83 | $2.72 |
| Distance from 52-week high | -76.68% | -57.17% |
| Average volume | 1.56M | 1.32M |
| Shares outstanding | 76.30M | 103.88M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LRMR has outperformed FULC by 18.5 percentage points over the past year.
FULC vs LRMR FAQ
Which is bigger, Fulcrum Therapeutics or Larimar Therapeutics?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $285.68M compared with $280.01M for Fulcrum Therapeutics (FULC).
Which stock has performed better over the past year, FULC or LRMR?
LRMR returned -41.74% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Fulcrum Therapeutics and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.